In order to clarify the safety of Ca-DTPA and Zn-DTPA recommended to use as drugs in the therapeutic removal of incorporated radionuclides from the human body, the teratological study on these two agents was carried out in rats as one of a series of the toxicological tests. The teratological effects of DTPA were observed because the fetus is highly susceptible to any drug. The pregnant females of Wistar rat were injected subcutaneously daily on days 9-13 of gestation with 1, 6, 12, 24 and 36 H. D. (H. D.=human dose, 1 H. D.= 30umol/kg body weight) of Ca-DTPA or Zn-DTPA, respectively. In the dams, no toxic effects were observed. In the fetuses, the decrease of the survival rate was observed in only the group injected daily with 36 H. D. of Ca-DTPA.
I INTRODUCTION
The administration of DTPA (diethylenetriaminepentaacetic acid) to a person is currently recommended in order to reduce the risk from radionuclide-induced cancer, because DTPA has received recognition to be effective in decorporating plutonium and other actinides from the body. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] However, the safety of DTPA in a human body as a drug has not been satisfactorily evaluated, although several toxicological examinations have been carried out in the experimental animals. [12] [13] [14] [15] [16] [17] [18] [19] [20] Before DTPA chelates are administered to a human in our country, the various toxicological data to evaluate their safety must be obtained.
In the present study, as one of a series of the toxicological tests to offer the data for evaluating the safety of DTPA, the teratological effects of Ca-DTPA and Zn-DTPA were observed in pregnant rats, because it is known that the fetus is highly susceptible to any drug.
II MATERIALS
AND METHODS
Experimental animals
Males and virgin females (10-14weeks old, 230-280g) of Wistar rat were caged together. The presence of a vaginal plug was examined each morning and was considered indicative of day 0 pregnancy. Pregnant females were divided into several groups and housed 2-6 animals in a cage of size of 34cm width x46cm depth x23cm height.
They were kept under the condition of the temperature of 22+2C, the moisture of 60+ 5%, and an alternating 12hr light-dark cycle. All animals were given feed (BM-1, Funabashi Farm Co. Ltd.) and tap water ad libitum. 4. Procedure of examination (1) Dams All pregnant rats were sacrificed on day 20 of gestation with chloroform. Under the anesthetized condition, the rats were weighed, incised the abdominal wall and then drawn the blood from the vena cava posterior. Blood examination was carried out for the red blood cell count, hematocrit value, haemoglobin value, and white blood cell count (Sysmex, Microcellcounter CC-120, TOA). Furthermore, the separated serum was examined for the values of glutamic-oxalacetic transaminase (GOT), glutamic-pyruvic transaminase (GPT) and alkaline phosphatase (ALP) activities with an autoanalyzer (Enzyme and substrate system, VITATRON) and for total protein. Thereafter, the pathological examination was done.
(2) Fetuses Number of fetuses and their status (living, dead or resorbed) were noted. The survival rate of fetuses was calculated as number of living fetus/ total number of implantation.
Fetuses were killed, weighed, and examined for gross defects. Thereafter the skin, fat and viscera of fetuses were removed. The skeleton was stained with alizarin red S and alcian blue,22) and anomalies of the skeleton were examined with a dissection microscope.
III RESULTS
Toxicity in dams
No clinical and pathological unusualities were found in any dam injected with DTPA. Table 1 shows the results of the blood and serum examinations of the dams. The data of all the DTPA groups did not show any significant difference 
Toxicity in fetuses
In of 36 H. D. Ca-DTPA group was significantly decreased. Table 3 shows the results of observation on the defects in the fetuses. The fusion of the first and second ribs of the fetuses was observed at high proportion in all the groups including the no treated (11.5%) and isotonic saline (16.0%) groups, and also often in dams. The gross defects observed in fetuses are as follows: exencephaly, four cases (3.4%) from the 24 H. D. Ca-DTPA group, fourteen cases (16.9%) from the 36 H. D. Ca-DTPA group and one case (0.8%) from the isotonic saline group; microphthalmia, four cases (4.8%), or anophthalmia, three cases (3.6%) from the 36 H. D. Ca-DTPA group; fusion of ribs except the first and second ribs, one case (1.0%) from the 12 H. D. Ca-DTPA group, one case (0.8%) from the 24 H. D. Ca-DTPA group and three cases (3.6%) from the 36 H. D. Ca-DTPA group; polydactyly, one case (0.8%) from the 12 H. D. Zn-DTPA group.
IV DISCUSSION
The teratological study using Wistar rats was performed by SIKov et al., 19) in which Ca-DTPA or Zn-DTPA was injected intraperitoneally on days 8 through 12 of gestation in various multiples of the human dose. They observed a slight diminution in the weight gain of the pregnant females and 80% mortality of the embryos in the 16 H. D. Ca-DTPA group and a decrease in the weight of pregnant females and the 100% mortality of the embryos in the 32 H. D. and 64 H. D. Ca-DTPA groups. On the other hand, in all the Zn-DTPA groups, any toxicity was not observed in the dams and fetuses. No toxicity of Zn-DTPA observed in both the dams and fetuses is quite consistent with our present results. Although no reasons of the marked difference of the effect of Ca-DTPA on the survival rate of embryos observed in the experiment by SIKOV et al. from the present ones are readily apparent, there are some differences of experimental conditions such as the injection route, the administration period and the producer of the rat, between the two experiments.
In the present study, exencephaly was observed at high proportion: 3.4% and 16.9% in the 24 H. D. and 36 H. D. Ca-DTPA groups, respectively. Microphthalmia and anophthalmia were observed at the rates of 4.8% and 3.6%, respectively, in the 36 H. D. Ca-DTPA group. Polydactyly was observed at the rate of 0.80% in the 12 H. D. Zn-DTPA group. It has been reported that the spontaneously occurring rates in rats of exencephaly, polydactyly and anophthalmia are 0.05%, 0.28% and 0.09%, respectively.23) One exencephaly observed in the isotonic saline control group might not have been affected by isotonic saline. Likewise, it is very probable that one polydatyly observed in the 12 H. D. Zn-DTPA group was not due to the effect of Zn-DTPA. This speculation might also be supported by the fact that the spontaneous occurrence of polydactyly is relatively high. The fusion of the first and second ribs was observed in all the groups. This defect was also observed at similar proportion (10.8%) in the fetuses of isotonic saline or no treated control group. Therefore, it is considered that the rats used in the present study have the defect inherently.
FISHER et al. 17) observed the defects such as exencephaly, ablepharia, spina bifida aperta, cleft palate, and polydactyly in the fetuses of the mouse injected subcutaneously with Ca-DTPA. Taylor et al.20) observed the abnormal hair color, death, neutropenia and lissencephally in the pups of pregnant beagles administered daily with only 1 H. D. of Ca-DTPA from 15 days after mating until parturition.
At least, these indicate that Ca-DTPA has a teratological effects on embryos. SIKov et al. also observed an increase in hydronephrosis, alteration in kidney structure and a few minor skeletal abnormalities in the fetuses. Although they mentioned that the teratological effects of DTPA, if any, were minor and sporadic in rats, the observations mentioned above show that Ca-DTPA should not be given to pregnant women.14)
Our result suggests that daily amount of Ca-DTPA to produce the fetal toxicity was 12-24 H. D. (360-720tmol/kg body weight). This value is similar to 230-460umol/kg body weight of Ca-DTPA which was obtained in rats by SIKov et al., 19) although the appearance of the effect of DTPA at these dose levels in the latter is far more drastic than that in the former. The fetal toxicity in mice was observed in the group given 720 cmol/kg body weight of Ca-DTPA. 17, 8) In this study, no untoward effects were observed Therefore, great care must be taken in the extrapolation of animal data to man.24) At any rate, it should be our choice that a pregnant woman must not be given Ca-DTPA.
However, no toxic effects of either Ca-DTPA or Zn-DTPA observed in the dams and of Zn-DTPA even in the fetuses indicate that these agents can be used by a radiation worker who usually is an adult man. 25) It is expected that we can take DTPA without anxiety just as a digestive or a vitamin tablet.
To accomplish this, however, further study to clarify the safety of DTPA as a drug must be performed.
